Companies / Australia
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Biota Ups Relenza Claim Against GSK
April 2007 | Legal NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
Australian biotechnology firm Biota has increased its damages claim against UK-based multinational GlaxoSmithKline, alleging that its senior development partner for its influenza drug Relenza (zanamivir) failed to promote the medicine properly, especially in the light of the potential avain flu pandemic. BMI sympathises with the smaller company, but it remains to be seen if GSK did indeed breach its contract. Regardless, we expect both companies to increase promotion of Relenza as countries around the world look to stockpile alternative anti-flu medicines as the image of competing product Tamiflu (oseltamivir)